General Biologicals Corp.
TTPEX:41177.30
TWD
+0.30
(+4.29%)
General Biologicals Corp.
TPEX:4117
(Taipei Exchange)
Recent
price
7.30
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.- Similar Companies
- Business
- General Biologicals Corporation (TWSE: 4117), founded in 1984 and headquartered in Hsinchu Science-Based Park, Taiwan, develops, manufactures and markets in-vitro diagnostics, precision medicine solutions, biopharmaceuticals and consumer healthcare products serving hospitals, laboratories, blood banks and clinics in over 40 countries across Asia, North America, the Middle East and South America. Its core offerings encompass immunoassay technologies including ELISA and chemiluminescence immunoassay (CLIA) systems such as the CL i120 analyzer and reagents for infectious diseases, hepatitis (A/B/C/D), HIV blood screening, tumor markers, thyroid function, hormones, cytokines, cardiac biomarkers and fertility testing; molecular diagnostics via the GBC AIO M160 all-in-one nucleic acid extraction, amplification and analysis platform with RealQuant kits for HBV, HCV and HPV; liquid biopsy technologies under the CellBio brand featuring iFiltration systems like FX10 and a2000 for circulating tumor cell (CTC) detection, monitoring and oncology applications; contract development and manufacturing organization (CDMO) services; blood screening and biomaterial solutions including antibodies and antigens; and P113 antimicrobial peptide pharmaceuticals for oral candidiasis, gingivitis and consumer products under the oh care brand covering oral care, feminine hygiene, baby care, skin care and pet applications. Subsidiaries and affiliates include CurieMed for diagnostic services in Taiwan, Danner Laboratory in the USA for clinical testing, Pacgen Life Science in Canada, GB GENES and DGBC in China. Recent developments feature the May 2025 commissioning of the GBC AI Biotech Building in Hsinchu's AI Smart Park as a hub for nine specialized centers in molecular diagnostics, precision medicine, protein drug R&D, stem cell culture and AI-driven digital pathology; TFDA approval and EU IVDR pursuit for the CL i120 CLIA analyzer driving equipment-plus-reagent sales; multiple CellBio awards including 2025 Taiwan Excellence, SNQ National Quality and National Pharmaceutical Technology Bronze; a three-year exclusive distribution deal with a Brazilian partner for ELISA, CLIA, PCR and hepatitis assays targeting South American blood centers and labs; expanded Fubon Life Insurance CTC testing collaboration exceeding 25,000 cases; and U.S. market launch of CellBio CTC products at AACC 2023 with ongoing global exhibitions.